KAIROS PHARMA, LTD.

NYSE: KAPA (Kairos Pharma, Ltd.)

Last update: yesterday, 5:38PM

0.436

-0.02 (-4.60%)

Previous Close 0.457
Volume 33,061
Avg. Volume (3M) 364,385
Market Cap 2,042,202
Price / Book 0.420
52 Weeks Range
0.381 (-12%) — 7.28 (1569%)
Diluted EPS (TTM) -2.09
Total Debt/Equity (MRQ) 4.26%
Current Ratio (MRQ) 6.77
Operating Cash Flow (TTM) -4.11 M
Levered Free Cash Flow (TTM) -2.55 M
Return on Assets (TTM) -65.65%
Return on Equity (TTM) -110.77%

AIStockmoo Score

-3.3
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Holdings' Sentiment info NA
News Mood info NA
Institutions net -3.72% of shares in their latest 13F filings: 5 holders increased, 11 decreased (quarter to 30 Sep 2026). info
Insider Activity info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Earnings per share have mostly fallen. Made a loss in recent years. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Short-term momentum falling. info
Price is near support. info
Final Score -3.26
Show all

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Kairos Pharma, Ltd. - -

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
KAPA 2 M - - 0.420 -3.3
CYBN 359 M - - - 0.0
NRXS 60 M - - 18.58 -1.2
CVM 21 M - - 2.22 -3.7
NHWK 20 M - - 0.260 0.0
AEON 10 M - - - -3.3

Select this tab to load the latest available analysis.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 24.29%
% Held by Institutions 3.45%

Ownership

Name Date Shares Held
Aptus Capital Advisors, Llc 30 Sep 2026 0
Sevenbridge Financial Group, Llc 30 Sep 2026 0

No data within this time range.

Institutions

Institutional ownership: 1.20%

Positions Holders Shares
Increased 5 14,551
Decreased 11 115,458
New 2 4,680
Sold out 9 89,782

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

0 Positive 0 Negative 2 Neutral
Date Type Details
05 Nov 2026 Yahoo Finance Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
LOS ANGELES, November 05, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for…
03 Nov 2026 Yahoo Finance Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
LOS ANGELES, November 03, 2026--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026…
22 Oct 2026 Yahoo Finance CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular…
06 Oct 2026 Yahoo Finance Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
LOS ANGELES, October 06, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with…
23 Sep 2026 Yahoo Finance Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the…
09 Sep 2026 Yahoo Finance Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global…

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It is close to them.
Nearest support: 0.362 – 0.437 · moderate level
Nearest resistance: 0.452 – 0.490 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria